Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04474223 · ClinicalTrials.gov registry record · Phase 3
Surveillance and Treatment to Prevent Fetal Atrioventricular Block Likely to Occur Quickly (STOP BLOQ)
A Phase 3 study of AVB - Atrioventricular Block and Fetal AVB, sponsored by NYU Langone Health.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 1,300
- Enrollment target
- 20
- Study locations
NCT04474223: Recruiting Phase 3 study of AVB - Atrioventricular Block and Fetal AVB, sponsored by NYU Langone Health.
NCT04474223 is a Phase 3 study of AVB - Atrioventricular Block and Fetal AVB that is actively recruiting participants, run by NYU Langone Health. The registered enrollment target is 1,300 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (68% higher). The trial reports 20 study locations across 14 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04474223, a Phase 3 study of AVB - Atrioventricular Block and Fetal AVB, is actively recruiting participants, sponsored by NYU Langone Health.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 1,300 participants
- Enrollment target
- 20
- Study locations
Study Summary
Fetal complete (i.e., third degree, 3°) atrioventricular block (AVB), identified in the 2nd trimester of pregnancy in an otherwise normally developing heart, is almost universally associated with maternal anti-Ro autoantibodies and results in death in a fifth of cases. To date treatment of 3° AVB has been ineffective in restoring normal rhythm (NR) which may be because current surveillance is limited to once- weekly fetal echocardiograms. It is hypothesized that there may be a vital transition period of several hours in which incomplete block (2° AVB) may be successfully treated avoiding fully advanced irreversible 3° AVB. To optimize the likelihood of timely detection of the transition period this study comprises three steps: 1) to risk stratify for high titer anti-Ro antibodies, which are necessary but not sufficient to develop fetal AVB; 2) to empower mothers to identify 2° AVB by using fetal heart rate and rhythm monitoring (FHRM) at home, and 3) to rapidly treat mothers who detect an abnormality by monitoring with an urgent echocardiogram that confirms 2° AVB with the hope of reversing 2° AVB before it becomes permanent (3° AVB). In addition, it will be determined if FHRM reduces the need for weekly echoes. Although mothers with low titer anti-Ro will not be continued in Step 2 and therefore not followed by FHRM, birth ECGs will be collected to confirm that low titer antibodies do not confer risk. It is anticipated that this study will provide an evidenced based surveillance strategy for those mothers at high risk of having a child with 3° AVB.
Primary Outcome
The presence of NR (normal rhythm) will be determined by electrocardiogram (ECG)
Conditions Studied
Interventions
- DRUG Dexamethasone
- DRUG IVIG
Study Locations (20)
California
- University of California - Los Angeles (UCLA) - Los Angeles
- Stanford University - Palo Alto
- University of California-San Francisco - San Francisco
New York
- NYU Langone Health - New York
- Mount Sinai - New York
- Columbia University Medical Center - New York
Kentucky
- University of Kentucky / Kentucky Children's Hospital - Lexington
- University of Louisville / Norton Children's Hospital - Louisville
Ohio
- UH Rainbow Babies / Children's Hospital - Cleveland
- Cleveland Clinic Lerner College of Medicine - Cleveland
Arizona
- Phoenix Children's Hospital/Dignity Health - Phoenix
Colorado
- University of Colorado, Denver (UCD) - Aurora
Connecticut
- Yale University School of Medicine - New Haven
District of Columbia
- Children's National Medical Center/George Washington University - Washington D.C.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,300 participants |
| Start Date | 2020-08-01 |
| Est. Completion | 2029-06-30 |
| Phase | Phase 3 |
What NCT04474223 shows while recruiting
NCT04474223 is an interventional study that assigns participants to a tested intervention. Its 1,300 participants enrollment target places it among the larger protocols in the corpus, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (68% higher).
The record links to 2 conditions, with AVB - Atrioventricular Block appearing as the primary indexed condition, and to 2 interventions - of which Dexamethasone is the first listed.
NCT04474223 names 20 study sites across 14 states, led by California, New York, Kentucky.
Frequently Asked Questions
What is clinical trial NCT04474223 about?
NCT04474223 is a clinical study titled "Surveillance and Treatment to Prevent Fetal Atrioventricular Block Likely to Occur Quickly (STOP BLOQ)". Fetal complete (i.e., third degree, 3°) atrioventricular block (AVB), identified in the 2nd trimester of pregnancy in an otherwise normally developing heart, is almost universally associated with maternal anti-Ro autoantibodies and results in death in a fifth of cases. To date treatment of 3° AVB ha...
What is the current status of trial NCT04474223?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 1,300 participants. The study started on 2020-08-01. Estimated completion is 2029-06-30.
What conditions does trial NCT04474223 study?
This clinical trial studies the following conditions: AVB - Atrioventricular Block, Fetal AVB.
What interventions are being tested in trial NCT04474223?
The interventions under investigation include: Dexamethasone (DRUG), IVIG (DRUG).
Who is sponsoring clinical trial NCT04474223?
This trial is sponsored by NYU Langone Health, which has 1,164 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04474223 being conducted?
This trial has 20 study locations across Arizona, California, Colorado, Connecticut, District of Columbia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04474223's enrollment target sits among peer trials
1,300 189th of 2000 higher than 1,807 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04792684 · 1,300 participants
Collection of Samples USOPTIVAL Study
- NCT05166694 · 1,300 participants · NA
Evaluating Personalized Therapeutics Clinic (PTC) on Drug-Drug Interactions and Drug-Gene Interactions
- NCT05282654 · 1,300 participants · NA
Real-time Symptom Monitoring Using ePROs to Prevent Adverse Events During Care Transitions
- NCT05705401 · 1,300 participants · Phase 3
Testing Radiation and HER2-targeted Therapy Versus HER2-targeted Therapy Alone for Low-risk HER2-positive Breast Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI